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nc-nd/4.0/).Abstract Aims: This review aims to describe the pathogenic role of triglycerides in cardiometa-
bolic risk, and the potential role of omega-3 fatty acids in the management of hypertriglyceride-
mia and cardiovascular disease.
Data synthesis: In epidemiological studies, hypertriglyceridemia correlates with an increased risk
of cardiovascular disease, even after adjustment for low density lipoprotein cholesterol (LDL-C)
levels. This has been further supported by Mendelian randomization studies where triglyceride-
raising common single nucleotide polymorphisms confer an increased risk of developing cardio-
vascular disease. Although guidelines vary in their definition of hypertriglyceridemia, they consis-
tently define a normal triglyceride level as <150 mg/dL (or <1.7 mmol/L). For patients with
moderatelyelevated triglyceride levels, LDL-C remains the primary target for treatment in both Eu-
ropean and US guidelines. However, since any triglyceride level in excess of normal increases the
risk of cardiovascular disease, even in patients with optimally managed LDL-C levels, triglycerides
are an important secondary target in both assessment and treatment. Dietary changes are a key
element of first-line lifestyle intervention, but pharmacological treatment including omega-3 fatty
acids may be indicated in people with persistently high triglyceride levels. Moreover, in patients
with pre-existing cardiovascular disease, omega-3 supplements significantly reduce the risk of
sudden death, cardiac death and myocardial infarction and are generally well tolerated.
Conclusions: Targeting resistant hypertriglyceridemia should be considered as a part of clinical
management of cardiovascular risk. Omega-3 fatty acids may represent a valuable resource to this
aim.
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Table 1 Classification of triglyceride levels according to a range of
guidelines/definitions [10].
Triglyceride level
mmol/L mg/dL
NCEP ATP III (2001)
Normal <1.7 <150
Borderline-high 1.7e2.3 150e200
High 2.6e5.6 200e500
Very high >5.6 >500
ESC/EAS guidelines (2011)
Normal <1.7 <150
Hypertriglyceridemia 1.7e9.9 150e880
Severe hypertriglyceridemia 10 880
Endocrine Society guidelines (2012)
Normal <1.7 <150
Medium 1.7e2.3 150e200
Moderate 2.3e11.2 200e1000
Severe 11.2e22.4 1000e1980
Very severe >22.4 >1980
EAS Consensus Panel 2014
Normal <2.0 <175
Mild-to-moderate 2.0e10.0 175e885
Severe >10.0 >885
EAS, European Atherosclerosis Society; ESC, European Society of
Cardiology; NCEP ATP, National Cholesterol Education Program
Adult Treatment Panel III.
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Although several studies have associated high plasma tri-
glycerides (TGs) with increased risk of cardiovascular dis-
ease (CVD) [1,2], the causal, independent contribution of
hypertriglyceridemia to cardiovascular risk remains
controversial [3]. The observation that individuals with
grossly elevated plasma TGs do not develop atheroscle-
rosis [4], further raised skepticism about the role of TGs in
CVD. As interventional studies aimed at reducing TGs have
shown inconsistent effects on CVD outcomes, hyper-
triglyceridemia has received less attention than hyper-
cholesterolemia in the management of cardiovascular risk.
However, in the last 10 years, data from Mendelian
randomization analyses have brought new attention to-
wards a direct causal association between levels of TG-rich
lipoproteins and the risk of CVD [5e7], and there is
increasing awareness that TGs may add to a patient’s risk
profile [8].
TGs are directly affected by the dietary intake of fats
and carbohydrate. In particular, the fact that diets rich in
omega-3 fatty acids (O3FAs) exert beneficial effect on
hypertriglyceridemia and are associated with reduced
rates of CVD [9] has raised interest in exploring the po-
tential of O3FAs in the management of hyper-
triglyceridemia as well as in reducing cardiovascular
risk. This review describes the pathogenic role of TGs in
cardiometabolic risk, the importance of TGs in cardiovas-
cular risk assessment, and the potential role of O3FAs
in the management of hypertriglyceridemia and CVD
prevention.
Clinical definition of hypertriglyceridemia
Various definitions of what constitutes elevated TGs have
been proposed (Table 1). In 2014, the European Athero-
sclerosis Society consensus panel suggested a definition of
normal TGs as <175 mg/dL (<2.0 mmol/L) and severe
hypertriglyceridemia as >885 mg/dL (>10.0 mmol/L) [10].
This recommendation is based on genetic studies indi-
cating that TGs in excess of 885 mg/dL probably have a
monogenic cause, particularly in younger people (Fig. 1). In
people with moderate hypertriglyceridemia (TGs of
175e885 mg/dL [2e10 mmol/L]), TG levels are likely to
result from an interaction of several genetic effects and
secondary risk factors [10].
Complicating the definition of hypertriglyceridemia is
the intraindividual variability in TGs over time [11]. TGs
are highest about 4 h after a meal [12], and postprandial
levels appear to be affected by the content of the meal, the
presence of diabetes, age and body mass index, as well as
genetic variants [13]. Taking a fasting sample is thought to
reduce the variability of TG measurements. However, a
nonfasting sample may more accurately reflect the pa-
tient’s usual metabolic state because it would reflect the
number of atherogenic remnant particles not cleared from
the circulation [12]. Importantly, a nonfasting TG level has
also been shown to be associated with the risk of CVD
[5,7,14e16].The 2011 statement from the American Heart Associa-
tion recommends taking a nonfasting TG sample to iden-
tify normal or optimal TG levels; a nonfasting level of
<200 mg/dL [<2.3 mmol/L] is commensurate with a fast-
ing level of <150 mg/dL [<1.7 mmol/L] [8]. A fasting
sample should then be taken in patients with a nonfasting
TG level of 200 mg/dL [2.3 mmol/L] to determine
borderline high/high/very high status [8]. Notably, non-
fasting TG levels should not be used to calculate LDL-C via
the Friedewald method [8] and in patients with high TG
levels, the Friedewald formula should not be used to
calculate LDL-C levels [17].
Mechanisms of hypertriglyceridemia
In normal conditions, endogenous lipids are packaged in
the liver into very low density lipoprotein (VLDL) particles
which contain TG as their main component, and dietary
lipids absorbed in the intestine are incorporated into
chylomicrons (Fig. 2) [18]. Chylomicrons are rapidly
cleared as their TG content is hydrolyzed by lipoprotein
lipase (LPL) at adipose and muscle tissue capillary beds,
releasing free fatty acids (FFA) that are used for cellular
metabolic activities [18]. This process leaves behind
chylomicron remnants. VLDL is similarly hydrolyzed by
LPL, leaving remnants of VLDL particles in the bloodstream
and intermediate-density lipoprotein (IDL) particles that
are smaller in size and enriched in cholesteryl esters [18].
LPL activity determines the levels of TG-rich lipoproteins
in the circulation.
Remnants are primarily cleared by the liver [19]. Re-
ceptors for these lipoproteins, including the LDL receptor,
Figure 1 Distribution of triglyceride levels within the population, and the likely genetic contribution of elevated triglyceride levels [10]. Reprinted
from Lancet Diabetes Endocrinol, Vol. 2, R.A. Hegele, H.N. Ginsberg, M.J. Chapman, B.G. Nordestgaard, J.A. Kuivenhoven, M. Averna et al., The
polygenic nature ofhypertriglyceridaemia: implications for definition, diagnosis, and management, pp. 655e66, 2014, with permission from Elsevier.
Hypertriglyceridemia and omega-3 fatty acids 199VLDL receptor, LDL receptor-related protein 1 (LRP1) and
heparan sulfate proteoglycans (HSPGs), are present on the
surface of hepatocytes where they facilitate hepatic
clearance of these lipoproteins [19]. Knockout mouse
models have shown that the LDL receptor is not rate
limiting in remnant clearance, and that TG-rich protein
clearance also requires LRP1. Another pathway for lipo-
protein clearance involves syndecan 1, a core component
of HSPG, which is essential for both the binding and
degradation of VLDL remnant particles [19].
Any disruption that causes increased production of chy-
lomicrons and/or VLDL particles or a reduction in their
metabolic breakdown will result in elevated TG levels [8].
Hypertriglyceridemia may be primary or secondary [20].
Primary causes of hypertriglyceridemia include familial
hyperchylomicronemia (a deficiency of LPL, leading to
increased chylomicron levels); familial hypertriglyceridemia,
characterized by an isolated elevation of VLDL; combined
hyperlipoproteinemia, characterized by increased levels of
VLDL and LDL; and familial dysbetalipoproteinemia, charac-
terized by increased IDL [20]. Secondary hyper-
triglyceridemia is often associatedwith lifestyle factors, such
as alcohol use, poordiet or physical inactivity, and commonly
occurs inpatientswithobesity,metabolic syndromeor type2
diabetes [20]. However, it may also occur as a result of
medication use; common culprit agents are corticosteroids,
estrogens, tamoxifen, isotretinoin and the cardioselective b-
blockers [20]. Many patients with secondary hyper-
triglyceridemia havemore than one condition that increases
their risk of elevated TGs [20].
The genetic architecture of hypertriglyceridemia is
complex (Fig. 1). On the basis of recent genetic data, it is
thought that severehypertriglyceridemia (TGs>10mmol/L)is likely to have a monogenic cause where loss-of-function
mutations in genes that regulate catabolism of TG-rich li-
poproteins (eg, LPL, APOC2, APOA5, LMF1, GPIHBP1) play a
major role. Conversely, the more common mild-to-
moderate hypertriglyceridaemia (TGs 2e10 mmol/L) is
typically multigenic, and results from the cumulative
burden of common and rare variants in more than 30 genes
[10]. However, even in patients with monogenic hyper-
triglyceridemia non-genetic, susceptibility factors are likely
to still play a role [20].
The identification of rare and common variants that
confer an increased risk of developing high TG levels or
high remnant cholesterol levels have been used to test the
hypothesis whether elevation of plasma TG might also be
associated with an increased risk of developing coronary
artery disease (CAD). This approach, usually defined as
Mendelian randomization, is aimed at determining the
prevalence or incidence of CAD in carriers versus non car-
riers of each genetic variant or their combination. This
approach appears to be particularly interesting in investi-
gating the relation between TG and CAD risk as it minimizes
problems with confounding and reverse causation. For
example, 10 genotype combinations determined by three
different TG-raising variants in the APOA5 gene increased
the risk of myocardial infarction (MI) by around 40% [5,6].
More recently, it has been reported that, compared with
46,703 non-carriers, 188 heterozygous carriers of an LPL-
damaging mutation had higher TGs and higher CAD risk
(odds ratio 1.84; 95% CI 1.35e2.51; p < 0.001). An analysis
of six common LPL variants demonstrated an odds ratio for
CAD of 1.51 per 1 standard deviation increase in TG [21]. In
addition, some genetic polymorphisms work in the oppo-
site direction to reduce the risk of developing elevated TG
Figure 3 KaplaneMeier estimate of the risk of death, MI or recurrent
ACS in patients with normal (<150 mg/dL [1.7 mmol/L]) or elevated
(150 mg/dL [1.7 mmol/L]) triglyceride levels after acute MI; all pa-
tients were receiving statins [27]. HR, hazard ratio; TG, triglycerides.
Figure 2 Triglyceride metabolism. Apo, apolipoprotein; HDL, high-
density lipoprotein; HTGL, hepatic triglyceride lipase; IDL,
intermediate-density lipoprotein; LDL, low-density lipoprotein; LPL,
lipoprotein lipase; VLDL, very low-density lipoprotein.
200 M. Arca et al.levels and CAD, including loss-of-function alleles in the
ANGPTL4 and APOC3 genes [15,22,23]. This wealth of genetic
data on TG metabolism and CAD risk provides a new and
strong support to the notion that TG-rich lipoproteins are
causally associated with CAD.
Clinical complications of hypertriglyceridemia
In patients with TG levels >1000 mg/dL (>11.3 mmol/L),
the usual pathway for lipid hydrolysis is overwhelmed,
and many more chylomicrons circulate in plasma, even in
the fasting state, instead of being cleared [8,24]. Chylo-
microns are too large to enter the arterial intima, and are
therefore not considered to be atherogenic until they are
converted to chylomicron remnants [25].
As a result of chylomicrons’ remnants depositing in
tissue, patients with primary chylomicronemia often pre-
sent with xanthomas on the trunk, buttocks, shoulders
and extremities [4]. Xanthomas are raised yellow papules
on the skin, which are histologically characterized by lipid-
containing macrophages. Other features of primary chy-
lomicronemia include lipemia retinalis (accumulation of
lipids in the retinal vessels) and hepatosplenomegaly
secondary to macrophage infiltration of the liver andspleen [4]. However, pancreatitis remains the most
potentially serious complication of chylomicronemia [4],
especially when levels exceed 1000 mg/dL [11.3 mmol/L]
[26].
For most patients with TG levels <1000 mg/dL
(<11.3 mmol/L), acute pancreatitis is less of a concern than
CVD. At these TG levels, the predominant lipid particles are
not chylomicrons, but chylomicron remnants and other
atherogenic particles. In both men and women, the risk of
CVD (MI, ischemic heart disease, and mortality) increases
significantly with increasing levels of nonfasting TGs
(p < 0.001) [16].
Miller and colleagues demonstrated that, in patients
who had experienced an MI and were receiving statins, TG
levels above normal (150 mg/dL [1.7 mmol/L]) were asso-
ciated with an increased risk of a recurrent ischemic event
(Fig. 3) [27]. In this study, every 10 mg/dL decrement in
TGs was associated with a 1.8% reduction in the risk of a
cardiovascular event, and this significant relationship
(p < 0.001) remained statistically significant after adjust-
ment for other risk factors, including LDL-C and HDL-C
[27].
The mechanisms by which elevated TG levels may cause
atherosclerosis are complex. TG-rich lipoproteins (in
particular those of relatively small size like the remnants)
can enter into the arterial wall where they are trapped. It is
interesting that TG-rich lipoproteins, unlike LDL particles,
can be taken up directly by macrophages, turning these
cells into foam cells, the hallmark cells of the atheroscle-
rotic plaque. It has also been speculated that once TG-rich
lipoproteins penetrate the arterial intima, the release of
FFAs and monoacylglycerols by TG hydrolysis may cause
severe inflammation and necrosis [28]. People with fasting
hypertriglyceridemia have abnormal postprandial lipid
profiles, which are characterized by hyperlipidemia that is
more pronounced and persists for longer than in normo-
lipedemic individuals [29,30]. Hypertriglyceridemia acti-
vates the plasma cholesteryl ester transfer protein (CETP),
which is responsible for intravascular lipid remodeling.
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proteins, such as VLDL and chylomicrons, to HDL and LDL
in exchange for cholesteryl esters [31,32]. Triglyceride-rich
HDL is then rapidly metabolized, while triglyceride-rich
LDL is converted to small dense LDL [32], which appears
to be involved in the atherogenic process [33].
Implications for patient management
As described earlier, patients with very high or severely
elevated TG levels are at risk of pancreatitis, and require
intensive lifestyle interventions including strict recom-
mendations about abstaining from alcohol and limiting
dietary fat intake [34]. Depending on the local guidelines,
this usually applies to patients with TGs >500 mg/dL
(5.6 mmol/L) or 885 mg/dL (10 mmol/L). Guidelines also
recommend pharmacological treatment with TG-lowering
therapy in patients who have TGs >500 mg/dL (5.6 mmol/
L) [34].
For patients with moderately elevated TG levels, LDL-C
remains the primary target for treatment in patients with
most types of dyslipidemia in both European and US
guidelines [17,26]. Nevertheless, the fact that any TG level
in excess of normal (150 mg/dL [1.7 mmol/L]) increases the
risk of CVD even in patients with optimally managed LDL-
C [27,35] highlights the importance of TG as a secondary
target in both assessment and treatment. The ESC/EAS
guidelines note that TGs should be taken into account as
part of a complete risk assessment and when determining
treatment for patients with dyslipidemia [17]. They also
recommend initiating treatment for patients with TGs
>200 mg/dL (2.3 mmol/L) [17].
Both US and European guidelines highlight the impor-
tance of lifestyle measures as the first step to reducing TG
levels, in particular weight loss, limiting alcohol intake and
avoiding too much sugar/fructose or saturated fat in the
diet [8,17]. Following a Mediterranean diet (which is rich
in monounsaturated fatty acids) also significantly reduces
TG levels, as well as increasing HDL-C [36]. Consumption
of fish is an important factor associated with cardiovas-
cular risk reduction, and the higher the O3FA level of the
fish, the greater the effect [37].
Guidelines acknowledge that a TG level of <150 mg/dL
(<1.7 mmol/L) is desirable, and if elevated TG or non-HDL-
C levels persist after lifestyle intervention and statin
therapy, a number of guidelines recommend the use of TG-
lowering agents, primarily fibrates or O3FAs [17,38].
Fibrates decrease TGs by w36%, non-HDL-C by w6%e
16%, and LDL-C byw8%, and increase HDL-C byw10% [39].
However, fibrate-induced increases in LDL-C may occur in
patients with severe hypertriglyceridemia. To date, car-
diovascular outcome studies of fibrates have produced
varied results, with some studies suggesting a benefit only
in hypertriglyceridemic patients with low HDL-C. In a
meta-analysis of 7389 patients with high TGs (>200 mg/dL
[2.3 mmol/L]), fibrate therapy decreased vascular events
by 25%, and in the 5068 patients with both high TGs and
low HDL-C (<40 mg/dL [1 mmol/L]), a 29% decrease in
vascular events was observed [40]. Fibrate therapy isassociated with a number of adverse effects, including
increases in creatinine levels, myopathy, and, in rare cases,
rhabdomyolysis, especially when used in combination
with other lipid-lowering therapies [41]. Therefore, addi-
tional therapeutic options must be considered.
O3FAs reliably reduce TGs by 20%e50% [8,42], and
affect both fasting and nonfasting levels. For this reason,
O3FAs supplements are one of the pharmacological ther-
apies recommended for patients with elevated TGs [17,26].
The role of omega-3 fatty acids in the management of
hypertriglyceridemia
Effects of omega-3 fatty acids on triglyceride metabolism
and their role in atheroprotection
Very long-chain O3FAs include docosahexaenoic acid
(DHA) and eicosapentaenoic acid (EPA) [43]. A number of
likely mechanisms contribute to the effect of O3FAs on TG
levels [34,44]. Firstly, O3FAs downregulate hepatic VLDL
production. They also reduce the amount of non-esterified
fatty acids that is delivered to the liver by upregulating b-
oxidation of fatty acids in the liver, adipose tissue, heart
and skeletal muscle, so fewer fatty acids are stored intra-
cellularly or released back into the circulation [44]. In
peripheral tissues, O3FAs increase fatty acid uptake by
adipocytes, cardiac and skeletal muscle cells, and coun-
teract the lipolytic release of non-esterified fatty acids
from adipose tissue by suppressing inflammation [44].
O3FA have been shown to reduce postprandial hyper-
triglyceridemia [45e47], as well as remnant lipoprotein
cholesterol and the TG content of chylomicrons and VLDLs
[47].
A recent review of interventional studies supported the
notion that O3FAs supplementation has relevant effect
neither on total or LDL-C though, in some cases, fish oil
consumption led to a slight increase in LDL-C levels,
especially when high PUFA doses were used [48]. How-
ever, it is noteworthy that different O3FAs might have
divergent effects on atherogenic lipoproteins when
administered alone. In fact, in a meta-analysis of ran-
domized controlled studies, DHA, but not EPA, was found
to significantly increase plasma LDL-C and HDL-C con-
centrations [49].
O3FA have been shown to have anti-atherogenic and
cardioprotective effects. O3FA decrease the levels of
apolipoprotein CIII, thereby reducing the inflammatory
changes associated with atherosclerosis and CVD [50].
Furthermore, both DHA and EPA improve endothelial
function [51,52] and reduce the biomarkers of platelet
activation [53].
Effects of diets rich in omega-3 fatty acid-rich on
hypertriglyceridemia
A study conducted in 20 healthy people showed that a
diet rich in fish decreased the concentrations of TG-rich
lipoproteins, LDL-C and HDL-C over the course of 24
weeks [54]. Furthermore, in a double-blind, randomized,
Table 2 Clinical trials of at least 1 year’s duration and published in the past 20 years, which have assessed the effect of omega-3 fatty acids on cardiovascular endpoints (other treatment arms in these
studies not included).
Reference Design Type of patients Treatments N Duration
(years)
Primary
endpoint
Difference vs
placebo or control
(95% CI)
P-value
Primary intervention studies
Yokoyama et al., 2007 [58] PROBE Hypercholesterolemic
Japanese pts on a statin
EPA 1.8 g/day 9326 Mean
4.6
Any major fatal or
nonfatal coronary event
HR 0.81
(0.69e0.95)
0.011
No EPA 9319
ORIGIN investigators
2012 [56]
R, DB High CV risk and
dysglycemia
n-3 PUFA 900
mg/day
6281 Median
6.2
Cardiovascular death HR 0.98
(0.87e1.10)
0.72
Placebo 6255
Risk and Prevention Study
Collaborative
Group, 2013 [64]
R, DB Multiple CV risk factors
of atherosclerotic
vascular disease
(not MI)
n-3 PUFA 1 g/day 6244 Median
5
Composite of death,
nonfatal MI, nonfatal
stroke
HR 0.97
(0.88e1.08)
0.58
Placebo 6269
AREDS2 Research
Group 2014 [67]
R, DB Age 50e85 years with
age-related macular
degeneration
n-3 PUFA
(EPA þ DHA)
1 g/day
2056 Median
4.8
Composite outcome of
time to the first
occurrence of CVD
mortality or morbidity
HR 0.95
(0.78e1.17)
0.64
No PUFA 2147
Secondary intervention studies
Singh et al., 1997 [65] R, DB Post acute MI Fish oil
(EPA þ DHA)
1.8 g/day
122 1 Total cardiac events RR 0.70
(0.29e0.90)
<0.05
Placebo 118
GISSI investigators
1999 [59]
R, OL Recent MI
(3 months)
n-3 PUFA 5666 3.5 Cumulative rate of
all-cause death, nonfatal
MI, and non-fatal stroke
RR 0.90
(0.82e0.99)
0.048
No PUFA 5668
Nilsen et al., 2001 [62] R, DB Post acute MI Fish oil (EPA þ
DHA)
3.4e3.5 g/day
150 2 At least one cardiac event Incidence:
28%
>0.05
Placebo 150 Incidence: 24%
Svensson et al.,
2006 [66]
R, DB Hemodialysis
pts with CVD
n-3 PUFA 1.7
g/day
103 2 Composite of acute MI,
angina requiring coronary
intervention, stroke, TIA,
PVD requiring surgical
intervention, or death
HR 1.04
(0.72e1.48)
0.85
Placebo 103
Galan et al., 2010 [61] R, DB History of CVD n3-PUFA
(EPA þ DHA)
600 mg/day
633 Median
4.7
First major CV event HR 1.08
(0.79e1.47)
0.64
Placebo 626
Kromhout et al.,
2010 [60]
R, DB History of MI n-3 PUFA
(EPA þ DHA)
400 mg/day
2404 3.3 Major CV event HR 1.01
(0.87e1.17)
0.93
Control 2433
Rauch et al., 2010 [63] R, DB Recent acute MI n-3 PUFA
(EPA þ DHA)
1 g/day
1925 1 Sudden cardiac death OR 0.95
(0.56e1.60)
0.84
Placebo 1893
CAD, coronary artery disease; CI, confidence intervals; CV, cardiovascular; CVD, cardiovascular disease; DB, double-blind; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HR, hazard ratio; MI,
myocardial infarction; OL, open-label; OR, odds ratio; PROBE, prospective, randomized, open-label, blinded endpoints; pts, patients; PUFA, polyunsaturated fatty acids; R, randomized; RR, relative
risk.
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Hypertriglyceridemia and omega-3 fatty acids 203crossover, interventional study where 16 men (aged 35e75
years old) substituted 80 g of their normal dietary fat
intake with one of two test fat diets, the first one con-
taining 5 g/100 g long chain (n-3) fatty acids and the
second with matched oleic acid, it was shown that, after 21
days, the omega-3 enriched diet lowered plasma tri-
glycerides by 27% and VLDL-TG by 32% [55].
The effects of supplementation with omega-3 fatty acids
on hypertriglyceridemia
An alternative way to employ O3FA in the treatment of
patients with hypertriglyceridemia is to use pharmaco-
logical preparations. These preparations usually contain
DHA þ EPA as ethyl esters [43]. Data from use of these
agents suggest that they may be effective in a number of
clinical conditions characterized by TG elevation. For
example, in patients with impaired glycemic control,
supplementation with O3FA produced significant re-
ductions in plasma TGs [56]. In addition, a meta-analysis of
20 randomized controlled trials has shown that in patients
with diabetes, supplementation with O3FA reduces plasma
TG by 21.3 mg/dL (0.24 mmol/L) [57]. Also in people at risk
of CVD, supplementation with EPA has been shown to
reduce triglyceridemia [58]. The effects of O3FA supple-
mentation in patients with existing CVD are less certain,
with one study reporting significant reductions in TGs in
patients who had a MI [59], while in another study no such
reductions were observed [60].
The role of omega-3 fatty acids in the management of
cardiovascular risk
Relevant studies of O3FAs were identified by conducting a
PubMed search of randomized controlled trials published
since January 1, 1997, with “omega-3”, “n-3”, “eicosa-
pentaenoic acid”, “docosahexaenoic acid”, or “icosapent
ethyl” in the title or abstract. Primary and secondary
intervention studies that examined cardiovascular end-
points, lasted for at least 1 year, and included a control arm
were considered.
To date, the long-term placebo-controlled clinical trials
with O3FAs have produced inconclusive data on their ef-
fects on cardiovascular outcomes (Table 2), but the vari-
ability is likely to result from the different patient
populations, endpoints, and doses used in these studies
[56,58e67]. Studies in which patients have received O3FAs
for primary prevention of cardiovascular events tended to
show no significant benefit [56,64,67], with the exception
of the JELIS study which showed a significant reduction in
cardiovascular events in hypercholesterolemic Japanese
patients who took O3FAs in addition to a statin [58]. Meta-
analyses of the placebo-controlled studies in patients with
pre-existing CVD have shown that O3FAs significantly
reduce the risk of sudden death, cardiac death and MI
[68,69]. This is consistent with data from a retrospective
analysis of outcomes among real-world (unselected) Ital-
ian patients prescribed O3FAs when discharged from
hospital after acute MI [70]. The risk of all-cause mortalityor recurrent MI was significantly reduced in the cohort
receiving O3FAs (n Z 2425) compared with those not
receiving them (n Z 8844), after adjustment for patient
characteristics and concurrent therapies [70]. O3FAs
reduced the risk of all-cause mortality by 24% (adjusted
hazard ratio 0.76 [95% CI 0.59e0.97]) and the risk of
recurrent MI by 35% (adjusted hazard ratio 0.65 [95% CI
0.49e0.87]) [70].
With the exception of the JELIS study in Japanese pa-
tients [58], there are limited data on the impact of adding
O3FAs to statin therapy in patients who require TG
lowering in addition to LDL-C lowering. Two trials, the
REDUCE-IT study (NCT01492361) and the STRENGTH study
(NCT02104817), are underway to investigate this. The
REDUCE-IT study is examining the effects of icosapent
ethyl on cardiovascular events in high-risk patients with
hypertriglyceridemia who are taking a statin, and is ex-
pected to be completed in December 2017. The STRENGTH
study is investigating the effect of O3FAs, in addition to a
statin, in individuals with hypertriglyceridemia, low HDL-C
levels who are at high risk for CVD. The estimated
completion date of the STRENGTH study is November
2019.
Despite the current lack of randomized controlled data,
the European Heart Association recommends treating
elevated TGs (>200 mg/dL [2.3 mmol/L]) in patients with
controlled LDL-C [17] by using fibrates as the first choice
and O3FAs in case of controindications [17].Conclusions
Mendelian randomization analyses strongly implicate
elevated TGs levels in the development of CVD. Con-
sumption of a diet rich in O3FAs can help to mitigate this
risk. Pharmacological doses of O3FAs lower TG levels and
may have other beneficial physiological effects on lipid
transport and atherosclerosis development. Meta-analyses
of clinical trials with these agents indicate a significant
reduction in the risk of recurrent MI when used as sec-
ondary prevention. Their role in primary prevention of
CVD is less clear, but data from large-scale clinical trials
will help to answer this question in the coming years.Conflicts of interest
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